MY137619A - 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions - Google Patents

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

Info

Publication number
MY137619A
MY137619A MYPI20033150A MYPI20033150A MY137619A MY 137619 A MY137619 A MY 137619A MY PI20033150 A MYPI20033150 A MY PI20033150A MY PI20033150 A MYPI20033150 A MY PI20033150A MY 137619 A MY137619 A MY 137619A
Authority
MY
Malaysia
Prior art keywords
xanthines
piperidin
amino
preparation
pharmaceutical compositions
Prior art date
Application number
MYPI20033150A
Other languages
English (en)
Inventor
Frank Dr Himmelsbach
Matthias Dr Eckhardt
Elke Dr Langkopf
Michael Dr Mark
Roland Dr Maier
Ralf R H Dr Lotz
Mohammad Dr Tadayyon
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31947613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY137619(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10238243A external-priority patent/DE10238243A1/de
Priority claimed from DE10312353A external-priority patent/DE10312353A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MY137619A publication Critical patent/MY137619A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
MYPI20033150A 2002-08-21 2003-08-19 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions MY137619A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10238243A DE10238243A1 (de) 2002-08-21 2002-08-21 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE10312353A DE10312353A1 (de) 2003-03-20 2003-03-20 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
MY137619A true MY137619A (en) 2009-02-27

Family

ID=31947613

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI20033150A MY137619A (en) 2002-08-21 2003-08-19 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
MYPI20083230A MY165643A (en) 2002-08-21 2003-08-19 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI20083230A MY165643A (en) 2002-08-21 2003-08-19 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

Country Status (39)

Country Link
EP (6) EP2070539A1 (member.php)
JP (6) JP4233524B2 (member.php)
KR (2) KR101150449B1 (member.php)
CN (4) CN102964347B (member.php)
AR (3) AR041025A1 (member.php)
AT (1) ATE453644T1 (member.php)
AU (2) AU2003253418B2 (member.php)
BE (1) BE2011C038I2 (member.php)
BR (2) BRPI0313648B8 (member.php)
CA (1) CA2496249C (member.php)
CY (3) CY1109928T1 (member.php)
DE (2) DE50312295D1 (member.php)
DK (1) DK1532149T3 (member.php)
EA (3) EA016166B1 (member.php)
EC (2) ECSP055617A (member.php)
EG (1) EG25011A (member.php)
ES (1) ES2339112T3 (member.php)
FR (1) FR11C0052I2 (member.php)
HK (1) HK1250708A1 (member.php)
HR (2) HRP20090665A2 (member.php)
HU (1) HUS1100028I1 (member.php)
IL (1) IL166964A (member.php)
IN (2) IN2015DN01132A (member.php)
LT (1) LTC1532149I2 (member.php)
LU (2) LU91889I2 (member.php)
ME (1) MEP59708A (member.php)
MX (1) MXPA05001684A (member.php)
MY (2) MY137619A (member.php)
NO (4) NO333970B1 (member.php)
PE (1) PE20040897A1 (member.php)
PL (2) PL216134B1 (member.php)
PT (1) PT1532149E (member.php)
RS (2) RS20120139A3 (member.php)
SA (1) SA03240448B1 (member.php)
SI (1) SI1532149T1 (member.php)
TW (3) TWI319320B (member.php)
UA (1) UA84275C2 (member.php)
UY (1) UY27946A1 (member.php)
WO (1) WO2004018468A2 (member.php)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE336494T1 (de) * 2002-05-31 2006-09-15 Schering Corp Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
CA2496249C (en) * 2002-08-21 2012-01-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (de) * 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
KR20050122220A (ko) 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
ZA200508439B (en) 2003-05-05 2007-03-28 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US7579357B2 (en) 2003-08-13 2009-08-25 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PT1706403E (pt) 2003-12-22 2012-04-23 Gilead Sciences Inc Compostos de imidazo[4,5-c]piridina e métodos de tratamento antiviral
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
EA200801601A1 (ru) * 2004-02-18 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх 8-[3-аминопиперидин-1-ил]ксантины, их получение и их применение в качестве ингибиторов dpp-iy
AU2012202850B2 (en) * 2004-02-18 2015-08-20 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a DPP inhibitor
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
KR101071390B1 (ko) 2004-03-15 2011-10-07 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
KR101238430B1 (ko) 2004-07-27 2013-02-28 길리애드 사이언시즈, 인코포레이티드 이미다조［4,5-ｄ］피리미딘, 그들의 용도 및 제조방법
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AU2012205240B2 (en) * 2004-11-05 2015-03-26 Boehringer Ingelheim International Gmbh Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines
PT1841765E (pt) 2004-12-21 2009-05-14 Gilead Sciences Inc Anticorpos para mcp-1 humano
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN102908351B (zh) † 2005-09-14 2014-07-23 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
US20070060530A1 (en) 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
EP1968947A1 (en) * 2005-12-23 2008-09-17 AstraZeneca AB Gaba-b receptor modulators
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
TW200803855A (en) * 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
PE20110235A1 (es) * 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
UA97244C2 (en) * 2006-05-04 2012-01-25 Берингер Ингельхайм Интернациональ Гмбх Polymorphs of 1-((4-methyfquinazolin-2-yl)methyl)-3-methyl-7- (2-butyn-1-yl)-8-(3-(r)-aminopiperidin-l-yl)xanthine
KR101143596B1 (ko) 2006-07-07 2012-05-11 길리애드 사이언시즈, 인코포레이티드 신규의 피리다진 화합물 및 이의 용도
WO2008017670A1 (en) * 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
PE20090597A1 (es) * 2007-08-16 2009-06-06 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
KR101610005B1 (ko) * 2007-08-17 2016-04-08 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ 관련 질환의 치료에 사용하기 위한 푸린 유도체
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CA2735562C (en) * 2008-08-15 2017-10-17 Boehringer Ingelheim International Gmbh Dpp-4 inhibitors for wound healing
MX2011002558A (es) * 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
UY32177A (es) * 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
CN107011345A (zh) * 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) * 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
CN102387795A (zh) 2009-02-13 2012-03-21 贝林格尔.英格海姆国际有限公司 包含dpp-4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
MA33046B1 (fr) 2009-02-13 2012-02-01 Boehringer Ingelheim Int Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp- iv et facultativemenet un autre agent antidiabetique et ses utilisations
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
NZ598366A (en) 2009-09-30 2014-03-28 Boehringer Ingelheim Int Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
HUE029381T2 (en) 2009-09-30 2017-02-28 Boehringer Ingelheim Int Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
EP2482812B1 (en) 2009-10-02 2023-01-11 Boehringer Ingelheim International GmbH Pharmaceutical compositions comprising bi-1356 and metformin
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
EP2545047B9 (en) 2010-03-10 2015-06-10 Probiodrug AG Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
CN102946875A (zh) * 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
PH12012502161A1 (en) 2010-05-05 2019-07-17 Boehringer Ingelheim Int Pharmaceutical formulations comprising pioglitazone and linagliptin
EA201991014A1 (ru) * 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
MX371198B (es) * 2010-11-15 2020-01-22 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora.
AR083878A1 (es) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US8785455B2 (en) 2011-05-10 2014-07-22 Sandoz Ag Polymorph of linagliptin benzoate
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20130123282A1 (en) 2011-11-16 2013-05-16 Leonid Metsger Solid state forms of linagliptin
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
CN103254193B (zh) * 2012-02-15 2015-04-22 上海医药工业研究院 黄嘌呤类化合物中间体及其制备方法
CN103254192B (zh) * 2012-02-15 2015-12-02 上海医药工业研究院 黄嘌呤类化合物、其盐、中间体、制备方法及应用
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2825539A1 (en) * 2012-03-12 2015-01-21 Cadila Healthcare Limited Amorphous form of linagliptin and process for preparation thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN103373999B (zh) * 2012-04-28 2016-01-13 上海医药工业研究院 嘌呤类化合物、中间体、制备方法及其应用
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
JP6374862B2 (ja) 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2854824A1 (en) 2012-05-25 2015-04-08 Boehringer Ingelheim International GmbH Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
CN103509023B (zh) * 2012-06-20 2014-08-27 成都苑东药业有限公司 黄嘌呤衍生物
CN103509022B (zh) * 2012-06-20 2015-04-01 成都苑东药业有限公司 黄嘌呤衍生物
ES2659563T3 (es) 2012-08-13 2018-03-16 Sandoz Ag Composición farmacéutica estable que contiene 8-[(3R)-3-amino-1-piperidinil]-7-(2-butin-1-il)-3,7-dihidro-3-metil-1-[(4-metil-2-quinazolinil) metil]-1H-purin-2,6-diona o una sal farmacéuticamente aceptable de la misma
US20150246117A1 (en) 2012-09-24 2015-09-03 Ulf Eriksson Treatment of type 2 diabetes and related conditions
CN103709163B (zh) * 2012-09-29 2016-12-21 齐鲁制药有限公司 黄嘌呤衍生物、其制备方法及用途
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN103319483B (zh) * 2012-10-19 2016-08-03 药源药物化学（上海）有限公司 一种利拉列汀重要中间体的制备方法
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US20150299200A1 (en) * 2012-12-17 2015-10-22 Mylan Laboratories Ltd An improved process for the preparation of linagliptin
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
CN103936740B (zh) * 2013-01-23 2016-06-29 成都苑东生物制药股份有限公司 黄嘌呤衍生物
CN103936738B (zh) * 2013-01-23 2016-11-23 成都苑东生物制药股份有限公司 黄嘌呤衍生物
CN103936737B (zh) * 2013-01-23 2016-09-14 成都苑东生物制药股份有限公司 黄嘌呤衍生物
CN103936739B (zh) * 2013-01-23 2016-08-31 成都苑东生物制药股份有限公司 黄嘌呤衍生物
JP2016510795A (ja) 2013-03-15 2016-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用
CA2906624A1 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN105377266A (zh) 2013-04-18 2016-03-02 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
CA2914791A1 (en) * 2013-06-14 2014-12-18 Boehringer Ingelheim International Gmbh Dpp-4 inhibitors for treating diabetes and its complications
CN104292228B (zh) * 2013-07-16 2016-03-30 成都苑东生物制药股份有限公司 一种黄嘌呤化合物的多晶型及其制备方法、用途
WO2015011609A1 (en) 2013-07-23 2015-01-29 Ranbaxy Laboratories Limited Process for the preparation of linagliptin and an intermediate thereof
CN104418857A (zh) * 2013-08-22 2015-03-18 北京蓝丹医药科技有限公司 无定型利格列汀及其制备方法
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
CN104725379A (zh) * 2013-12-24 2015-06-24 杭州民生药物研究院有限公司 嘌呤酮衍生物及其组合物的制备方法与用途
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104557935B (zh) * 2015-01-27 2016-08-17 江苏嘉逸医药有限公司 制备(r)-8-(3-氨基哌啶-1-基)-黄嘌呤的提纯方法
KR20180006881A (ko) 2015-03-09 2018-01-19 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016207364A1 (en) 2015-06-25 2016-12-29 Boehringer Ingelheim International Gmbh Process for the preparation of a xanthine-based compound
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US10668073B2 (en) 2015-10-09 2020-06-02 Hexal Ag Pharmaceutical composition containing 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof
EP3156048A1 (en) 2015-10-13 2017-04-19 Galenicum Health S.L. Stable pharmaceutical composition of linagliptin in the form of immediate release tablets
CN105566271B (zh) * 2015-12-03 2019-09-13 福建医科大学 双黄酮化合物及其制备治疗癌症的药物的用途
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물
WO2018087132A1 (en) 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2018104263A1 (en) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
KR102469957B1 (ko) 2017-06-30 2022-11-24 한미약품 주식회사 리나글립틴, 메트포르민 및 항산화제를 포함하는, 안정성이 개선된 약제학적 조성물
CN107325114B (zh) * 2017-07-04 2019-06-11 吉林省爱诺德生物工程有限公司 一种头孢洛林酯中间体的制备方法
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
KR102500835B1 (ko) 2017-10-24 2023-02-17 한미약품 주식회사 리나글립틴 및 메트포르민을 포함하는 복합제제 및 그의 제조방법
CN108299436B (zh) * 2018-02-09 2020-01-17 上海慈瑞医药科技股份有限公司 黄嘌呤类化合物及其药物组合物和应用
KR102208009B1 (ko) * 2018-04-26 2021-01-28 주식회사 경보제약 신규한 리나글립틴 염 화합물, 이의 제조 방법 및 신규한 리나글립틴 염 화합물로부터 제조된 리나글립틴
KR102647472B1 (ko) 2018-07-31 2024-03-14 한미약품 주식회사 디펩티딜 펩티다아제-4 억제제 및 메트포르민을 포함하는 경구용 고형 복합제제 및 이의 제조방법
HU231374B1 (hu) 2018-08-06 2023-04-28 Richter Gedeon Nyrt. Eljárás BOC-Linagliptin előállítására
EP3936192B1 (en) 2019-03-06 2025-04-09 Daiichi Sankyo Company, Limited Pyrrolopyrazole derivative
CN110305131B (zh) * 2019-07-03 2021-12-31 山东百诺医药股份有限公司 利格列汀新晶型及其制备方法
EP3811930A1 (en) 2019-10-24 2021-04-28 Authenda Pharmaceuticals AG Oral gliptin compositions and method for preparation thereof
WO2021109970A1 (zh) * 2019-12-02 2021-06-10 成都苑东生物制药股份有限公司 一种黄嘌呤衍生物药物组合物及其制备方法
WO2021160608A1 (en) 2020-02-13 2021-08-19 Zakłady Farmaceutyczne POLPHARMA S.A. Pharmaceutical composition comprising linagliptin and metformin
CN112876409A (zh) * 2021-01-20 2021-06-01 都创(上海)医药科技股份有限公司 一种2-(5-溴-6-甲氧基吡啶-2-基)乙腈及其衍生物的合成方法
SI4373482T1 (sl) 2021-07-22 2025-09-30 Krka, D.D., Novo Mesto Postopek za pripravo farmacevtskega sestavka, ki vsebuje linagliptin in metforminijev klorld
KR20230055762A (ko) 2021-10-19 2023-04-26 한미약품 주식회사 메트포르민, 리나글립틴 및 메글루민을 포함하는 약제학적 복합제제
EP4482835A1 (en) 2022-02-21 2025-01-01 KRKA, D.D., Novo Mesto Process for purification of linagliptin
KR20230126664A (ko) 2022-02-23 2023-08-30 주식회사 제뉴원사이언스 리나글립틴 또는 이의 약학적으로 허용가능한 염과 메트포르민 또는 이의 약학적으로 허용가능한 염을 포함하는 약물방출이 조절된 약제학적 복합제제
CN114989147B (zh) * 2022-06-20 2024-05-17 广东晨康生物科技有限公司 一种苯并嘧啶类化合物或其药学上可接受的盐及其制备方法和应用
EP4349837A1 (en) 2022-10-05 2024-04-10 Zaklady Farmaceutyczne "Polpharma" S.A. A pharmaceutical intermediate
WO2024091863A1 (en) 2022-10-25 2024-05-02 Starrock Pharma Llc Combinatorial, and rotational combinatorial therapies for obesity and other diseases
WO2025227129A2 (en) 2024-04-25 2025-10-30 Starrock Pharma Llc Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
CN118496229A (zh) * 2024-05-13 2024-08-16 迪嘉药业集团股份有限公司 一种利格列汀新晶型及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061753A (en) * 1976-02-06 1977-12-06 Interx Research Corporation Treating psoriasis with transient pro-drug forms of xanthine derivatives
FR2558162B1 (fr) * 1984-01-17 1986-04-25 Adir Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
FR2654935B1 (fr) * 1989-11-28 1994-07-01 Lvmh Rech Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
US5965555A (en) * 1996-06-07 1999-10-12 Hoechst Aktiengesellschaft Xanthine compounds having terminally animated alkynol side chains
AU6797298A (en) 1997-04-15 1998-11-11 Genentech Inc. Halo-alkoxycarbonyl prodrugs
DE19828114A1 (de) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
PT1741445E (pt) * 2000-01-21 2013-11-11 Novartis Ag Combinações incluindo inibidores de dipeptidilpeptidase-iv e agentes antidiabéticos
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
HUP0301622A3 (en) * 2000-07-04 2006-05-29 Novo Nordisk As Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them
DK1953162T3 (da) * 2001-02-24 2012-09-10 Boehringer Ingelheim Pharma Xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel.
DE60225556D1 (de) * 2001-07-03 2008-04-24 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
AU2002331311A1 (en) * 2001-09-19 2003-04-01 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
EP1496877B1 (en) * 2002-01-11 2008-10-01 Novo Nordisk A/S Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
CA2496249C (en) * 2002-08-21 2012-01-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
DE10251927A1 (de) * 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
JP2016199572A (ja) 2016-12-01
JP2012162555A (ja) 2012-08-30
WO2004018468A2 (de) 2004-03-04
NO20140234L (no) 2005-03-03
NO2014008I1 (no) 2014-06-02
MXPA05001684A (es) 2005-04-19
NO20130968L (no) 2005-03-03
IL166964A (en) 2011-02-28
CY2012001I2 (el) 2016-12-14
ATE453644T1 (de) 2010-01-15
JP2009079061A (ja) 2009-04-16
HK1250708A1 (zh) 2019-01-11
AU2010201384A1 (en) 2010-04-29
TW201304782A (zh) 2013-02-01
FR11C0052I1 (member.php) 2012-01-06
CA2496249C (en) 2012-01-24
BRPI0313648B8 (pt) 2021-05-25
EP3424926A1 (de) 2019-01-09
FR11C0052I2 (fr) 2013-01-11
DE122011100059I1 (de) 2012-04-05
HUS1100028I1 (hu) 2016-07-28
PL403104A1 (pl) 2013-05-13
ME00396B (me) 2011-05-10
JP2009001565A (ja) 2009-01-08
HRP20050157A2 (en) 2006-05-31
LTC1532149I2 (lt) 2025-03-10
EP1532149B9 (de) 2011-04-20
HK1134076A1 (en) 2010-04-16
JP4233524B2 (ja) 2009-03-04
CA2496249A1 (en) 2004-03-04
PE20040897A1 (es) 2005-01-31
BRPI0313648B1 (pt) 2018-07-17
JP4971251B2 (ja) 2012-07-11
UY27946A1 (es) 2004-03-31
AR041025A1 (es) 2005-04-27
HK1134077A1 (zh) 2010-04-16
KR101111101B1 (ko) 2012-06-13
JP5623459B2 (ja) 2014-11-12
HRP20090665A2 (hr) 2010-07-31
RS20120139A2 (sr) 2012-10-31
EA024251B1 (ru) 2016-08-31
JP2006503013A (ja) 2006-01-26
KR20090047560A (ko) 2009-05-12
PL216134B1 (pl) 2014-03-31
JP6139004B2 (ja) 2017-05-31
NO20050069L (no) 2005-03-03
BR122012026540B8 (pt) 2021-05-25
JP6114231B2 (ja) 2017-04-12
LTPA2011013I1 (lt) 2011-11-25
EP2060573A2 (de) 2009-05-20
EP2060573A3 (de) 2011-04-13
EP1532149B1 (de) 2009-12-30
BE2011C038I2 (member.php) 2022-08-09
HK1215439A1 (zh) 2016-08-26
CY1109928T1 (el) 2014-09-10
LU91889I9 (member.php) 2019-01-03
PL375342A1 (en) 2005-11-28
CY2012001I1 (el) 2016-12-14
EP2070539A1 (de) 2009-06-17
CN100522962C (zh) 2009-08-05
RS20050137A (sr) 2007-11-15
TW200944209A (en) 2009-11-01
RS20120139A3 (en) 2015-02-27
IN2015DN01133A (member.php) 2015-06-26
ECSP055617A (es) 2005-05-30
MEP59708A (en) 2011-05-10
KR20050058375A (ko) 2005-06-16
AU2003253418B2 (en) 2010-04-22
IN2015DN01132A (member.php) 2015-06-26
LU91889I2 (fr) 2011-12-21
TWI469783B (zh) 2015-01-21
SI1532149T1 (sl) 2010-05-31
AU2010201384B2 (en) 2013-05-02
NO2014008I2 (no) 2014-04-08
NO333970B1 (no) 2013-11-04
EA201001167A1 (ru) 2011-02-28
CN105001222B (zh) 2017-11-07
NO336641B1 (no) 2015-10-12
DK1532149T3 (da) 2010-05-10
EA200500302A1 (ru) 2005-10-27
TWI388325B (zh) 2013-03-11
PT1532149E (pt) 2010-02-17
AR087287A2 (es) 2014-03-12
EP2058311A2 (de) 2009-05-13
TW200404542A (en) 2004-04-01
SA03240448B1 (ar) 2009-06-07
JP5351486B2 (ja) 2013-11-27
BR0313648A (pt) 2007-05-08
CN102964347A (zh) 2013-03-13
CY2013002I1 (el) 2020-05-29
EP2308878A2 (de) 2011-04-13
CN1675212A (zh) 2005-09-28
CN105001222A (zh) 2015-10-28
HRP20050157B1 (en) 2013-01-31
LU92128I2 (fr) 2013-03-11
AU2003253418A1 (en) 2004-03-11
EP2308878A3 (de) 2011-10-26
KR101150449B1 (ko) 2012-06-01
EA010303B1 (ru) 2008-08-29
WO2004018468A3 (de) 2004-04-08
EA016166B1 (ru) 2012-02-28
EP1532149A2 (de) 2005-05-25
TWI319320B (en) 2010-01-11
CN107674077A (zh) 2018-02-09
RS52142B (sr) 2012-08-31
EG25011A (en) 2011-05-25
UA84275C2 (ru) 2008-10-10
HK1081552A1 (en) 2006-05-19
DE50312295D1 (de) 2010-02-11
ES2339112T3 (es) 2010-05-17
EA200702022A1 (ru) 2008-06-30
JP2014177485A (ja) 2014-09-25
AU2010201384C1 (en) 2013-09-26
BR122012026540B1 (pt) 2019-04-24
CN102964347B (zh) 2015-11-18
MY165643A (en) 2018-04-18
EP2058311A3 (de) 2011-04-13
HK1183028A1 (zh) 2013-12-13
AR077875A2 (es) 2011-09-28
ECSP12005617A (es) 2012-04-30

Similar Documents

Publication Publication Date Title
MY165643A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
MXPA05002014A (es) Acidos nucleicos inmunoestimuladores.
WO2006091915A3 (en) Immunostimulatory oligonucleotides
TNSN07150A1 (en) Semi-soft c-class immunostimulatory oligonucleotides
WO2005018555A3 (en) Lipid-modified immune response modifiers
SG167667A1 (en) Nucleic acid compositions for stimulating immune responses
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
ATE426412T1 (de) Adjuvante influenza-vakzine
EP1728863A3 (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency
DE60132474D1 (de) Ein immunostimulierendes nukleotid und ein tocol enthaltende zusammensetzung
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
MY129263A (en) Vaccine composition
WO2004030608A3 (en) Nanoemulsion vaccines
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
GB2386072A (en) Novel vaccine
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
SE0300457D0 (sv) Novel compounds
MY127452A (en) Vaccines.
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
TNSN05052A1 (en) Immunostimulatory nucleic acids
SG147465A1 (en) Vaccine
PL1615656T3 (pl) Produkt immunomodulatorowy otrzymany z hodowli bifidobacterium i zawierające go kompozycje
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
SG146693A1 (en) P185neu-encoding dna and therapeutical uses thereof